Best of ASTRO 2017
Czech Republic

19. 3. 2018

Kongresové centrum Kunětická Hora Dříteč
09:15 - 09:30  Welcome
Martin Doležel

09:30 - 10:10  Track 1 – Gastrointestinal (Renata Soumarová)

Abstract 1: (306) Enteral Nutrition Improves Nutritional Status, Treatment Tolerance and Outcomes in Patients with Esophageal Cancer Undergoing Concurrent Chemoradiation Therapy: Results of a Prospective, Randomized, Controlled, Multicenter Trial (NCT 02399306)

Abstract 2: (307) Phase II Study of Adjuvant Chemoradiation Therapy Using Docetaxel/Cisplatin/5-Fluorouracil Before and After Intensity-modulated Radiation Therapy with Concurrent Docetaxel in Patients with Completely (R0) Resected Gastric Carcinoma

Abstract 3: (308) Dose Escalation in Locally Advanced Pancreatic Cancer Patients Receiving Chemoradiation Therapy

Abstract 4: (191) Neutrophils Predicting Tumor Local Control After Chemoradiation Therapy in Locally Advanced Pancreatic Carcinoma in the LAP 07 Trial

Abstract 5: (192) The Clinical Implications of Soluble PD-L1 in Hepatocellular Carcinoma Patients Treated with Radiation Therapy

Abstract 6: (311) Improved Local Control with Stereotactic Body Radiation Therapy Compared to Radiofrequency Ablation in the Treatment of Unresectable Intrahepatic Metastases

Abstract 7: (144) Non-operative Management for Locally Advanced Rectal Cancer in the Veterans Health Administration

Abstract 8: (138) NRG Oncology/RTOG 0529: Long-term Outcomes of Dose-painted Intensity Modulated Radiation Therapy, 5-Fluorouracil and Mitomycin-C in Anal Canal Cancer
Abstract 1: (LBA-1) A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients with High-risk, Early Stage Endometrial Cancer: A Gynecology Oncology Group Study

Abstract 2: (48) Distinct Profile of Circulating Endothelial Progenitor Cells and Apoptotic Endothelial Cells During Chemoradiation as Individualized Biomarkers for Long-term Prognosis and Severe Toxicity in Cervical Cancer Patients

Abstract 3: (50) Expression of DNA Repair Genes in Cervix Cancer Patients Undergoing CCRT

Abstract 4: (241) Increased Diversity of the Intestinal Microbiome Predicts for Lower Rates of Patient Reported Acute Gastrointestinal Toxicity in Women Receiving Radiation Therapy for Cervical Cancer

Abstract 5: (239) Adjuvant Chemoradiation Therapy for Clear Cell Carcinoma of the Ovary: A Population based Study of Pelvic Versus Whole Abdominal Radiation Therapy

Abstract 6: (55) Outcomes and Patterns of Relapse Following Definitive Radiation Therapy for Treatment of Oligometastatic Cervical Cancer

Abstract 7: (242) Multi-institutional Analysis of Vaginal Brachytherapy Without External Beam Radiation Therapy for Stage II Endometrial Cancer Patients

Abstract 8: (1134) Improved Disease Control with Adjuvant Therapy for Stage IA Serous and Clear Cell Uterine Cancer: A Pooled Multi-institutional Analysis

Abstract 9: (1128) Vaginal Brachytherapy Boost in Margin Positive Early Stage Cervical Cancer
Track 3 – Genitourinary (Karel Odrážka)

Abstract 1: (1082) Low-Dose-Rate Brachytherapy for Prostate Cancer: Outcomes Beyond 10-years of Follow-Up

Abstract 2: (1) A Prospective Phase II Trial of Transperineal Ultrasound-guided Brachytherapy for Locally Recurrent Prostate Cancer after External Beam Radiation Therapy (NRG/RTOG 0526): Initial Report of Late Toxicity Outcome

Abstract 3: (282) Extremely Dose-escalated Radiation Therapy Improves Cancer-Specific Survival Compared With Radical Prostatectomy or Conventionally Dose-escalated Radiation Therapy in Gleason Score 9-10 Prostate Adenocarcinoma: A Multi-institutional Analysis of 1,403 Patients

Abstract 4: (336) 5-Year Outcomes of a Phase I Dose Escalation Study Using Stereotactic Body Radiosurgery for Patients With Clinically Localized Prostate Cancer

Abstract 5: (209) Multi-institutional Outcomes of Postprostatectomy Adjuvant Versus Early Salvage Radiation Therapy in Prostate Cancer Patients With Adverse Pathologic Features

Abstract 6: (210) Development and Validation of a Novel Clinical-Genomic Risk Group Classification for Prostate Cancer Incorporating Genomic and Clinicopathologic Risk

Abstract 7: (LBA-9) 68Ga-PSMA PET/CT Mapping of Early Biochemical Recurrence (PSA <1 ng/mL) after Primary Surgery in 270 Patients: Impact on Salvage Radiotherapy Planning

Abstract 8: (330) Individual Patient Data Metaanalysis of SBRT Kidney: A Report from the International Radiosurgery Oncology Consortium for Kidney (IROCK)

Abstract 9: (1089) The Use of Chemotherapy Instead of Radiation Therapy Does Not Reduce the Incidence of Second Cancers in Survivors of Early Stage Seminoma: A Population-based Study from British Columbia
Abstract 1: (33) Long-term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized Phase II Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients with Stage I Peripheral Non– small Cell Lung Cancer

Abstract 2: (35) SBRT for Central Tumors in Early Stage NSCLC Patients

Abstract 3: (224) The International Atomic Energy Agency Randomized Trial on Chemotherapy With or Without Radiation Therapy in Advanced Non–small Cell Lung Cancer (NCT00864331)

Abstract 4: (223) Quality of Life Outcomes in a Phase III Randomized Trial of Optimization of Treatment of Advanced Non–small Cell Lung Cancer Using Radiation Therapy and Chemotherapy: IAEA Multicentric Randomized Phase 3 Study (NCT00864331)

Abstract 5: (227) Long-term Results of RTOG 0617: A Randomized Phase III Comparison of Standard Dose Versus High Dose Conformal Chemoradiation Therapy +/- Cetuximab for Stage III NSCLC

Abstract 6: (226) PET-adjusted Intensity Modulated Radiation Therapy for Locally Advanced Non–small Cell Lung Cancer: A Prospective Trial

Abstract 7: (327) Heart Dosimetric Analysis of Three Types of Cardiac Toxicity in Patients Treated on Doseescalation Trials for Stage III Non–small Cell Lung Cancer

Abstract 8: (225) Continuous Intravenous Infusion Recombinant Human Endostatin Combined with Concurrent Chemoradiation Therapy in Unresectable Stage III Non–small Lung Cancer—Results of a Multicenter Phase II Study (NCT01733589)

Abstract 9: (LBA-4) PACIFIC: A Double-blind, Placebo-controlled Phase III Study of Durvalumab as Consolidation Therapy after Chemoradiation in Patients with Locally Advanced, Unresectable NSCLC

Abstract 10: (LBA-3) Consolidative Radiotherapy for Limited Metastatic Non-small Cell Lung Cancer (NSCLC): A Randomized Phase II Trial

Abstract 11: (323) Incidence of Pneumonitis in Metastatic Lung Cancer Patients Receiving Immune Checkpoint Inhibitors With or Without Thoracic Radiation Therapy

Abstract 12: (LBA-5) Phase II 5-arm Trial of Ipilimumab Plus Lung or Liver Stereotactic Radiation for Patients with Advanced Malignancies
Abstract 1: (5) Hypofractionated Radiation Therapy After Mastectomy for the Treatment of High-risk Breast Cancer: Five-year Follow-up Result of a Randomized Trial

Abstract 2: (7) Evaluating Radiation Omission Decisions in a Population-based Sample of Older Adults Receiving Lumpectomy for Breast Cancer

Abstract 3: (8) Single Stage Permanent Implant Reconstruction Has Better Outcome Than Tissue Expander/Implant in Patients Treated with Postmastectomy Radiation

Abstract 4: (9) Postmastectomy Radiation Therapy for Node-negative Breast Cancer with Tumor Size of Five Centimeter or More: A Meta-analysis

Abstract 5: (10) Lymphedema Risk Following Regional Nodal Irradiation in Breast Cancer: Implications for Field Arrangement and Treatment Volume

Abstract 6: (120) Local-regional Recurrence in Women with N0/N1mi, HER2-Positive Breast Cancer: Results from a Prospective Multi-institutional Study (The APT Trial)

Abstract 7: (13) Hypofractionated Whole Breast Irradiation in Women Less Than 50 Years Old Treated on Prospective Protocols: A Report on Long-term Cosmesis

Abstract 8: (116) Oncotype Score as a Predictor of Local-regional Recurrence in Early Stage Breast Cancer (BC)
Abstract 1: (292) A Personalized Approach Using Hypoxia Resolution to Guide Curative-intent Radiation Therapy Dose-reduction to 30 Gy: A Novel De-escalation Paradigm for HPV-associated Oropharynx Cancers Treated with Concurrent Chemoradiation Therapy

Abstract 2: (290) A Phase II Dose and Volume De-escalation Trial for High- and Low-risk HPV+ Oropharynx Cancer: Efficacy, Toxicity and Dosimetric Analyses

Abstract 3: (92) Quantification of HPV-16 in Circulating Tumor DNA During De-intensified Chemoradiation Therapy for Favorable-risk HPV-associated Oropharyngeal Squamous Cell Carcinoma

Abstract 4: (293) Nodal Radiographic Prognostic Factors in the New Stage I p16-Positive Oropharyngeal Cancer of the AJCC 8th Edition: Is All N1 Disease the Same?

Abstract 5: (97) Development of Laryngeal Cancer Nomograms from Pooled Data of Two Trials of Concurrent Chemoradiation: NRG Oncology RTOG 0129 and RTOG 0522

Abstract 6: (261) The Impact of Total Laryngectomy on Non-oncologic Causes of Death in Patients Treated with Radiation Therapy for Advanced Larynx and Hypopharynx Cancer

Abstract 7: (263) Comparison of Electronic Brachytherapy and Mohs Micrographic Surgery—A Matched Pair Cohort Study for Treatment of Nonmelanoma Skin Cancer

Abstract 8: (259) Eating as Treatment: A Stepped Wedge Randomized Controlled Trial to Improve Nutrition in Head and Neck Cancer Patients Undergoing Radiation Therapy
Abstract 1: (298) Phase II Study of Dose-reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma

Abstract 2: (131) Rainbows and Butterflies: Individualized IMRT Planning for Mediastinal Lymphoma

Abstract 3: (132) Non-coplanar Butterfly VMAT and Deep Inspiration Breath Hold for Mediastinal Lymphoma: Do We Need Both?

Abstract 4: (130) Dosimetric Comparison of Intensity Modulated Radiation Therapy via Breath Hold Technique and Proton Therapy With or Without Breath Hold for Mediastinal Lymphoma

Abstract 5: (136) Potential to Reduce Toxicity: Clinical and Dosimetric Predictors of Hypothyroidism After Radiation Therapy With IMRT for Hodgkin Lymphoma

Abstract 6: (299) Cardiac Disease and Lifestyle Risk Factors Following Hodgkin Lymphoma: An EORTC Lymphoma Group and GELA Follow-up Study

Abstract 7: (302) Role of Adjuvant Radiotherapy for Early-stage Anaplastic Large Cell Lymphoma: Analysis of the National Cancer Database

Abstract 8: (303) Impact of Consolidation Radiation Therapy in Stage III-IV Hodgkin Lymphoma After Complete Metabolic Response by Gallium or PET-CT

Abstract 9: (137) Augmented Total Body Irradiation With a Cranial Boost Before Stem Cell Transplantation Protects Against Posttransplant CNS Relapse in Acute Lymphoblastic Leukemia

Abstract 10: (135) Importance of PET-CT Radiomics Features in Outcomes Prognostication for Mediastinal Hodgkin Lymphoma
Track 8 – Central Nervous System

(Pavel Šlampa, Tomáš Kazda)

Abstract 1: (214.5) High-risk Meningioma: Initial Outcomes from NRG Oncology/RTOG 0539

Abstract 2: (217) Does the Addition of Valproic Acid to Concurrent Radiation Therapy and Temozolomide Improve Patient Outcome? Correlative Analysis of RTOG 0525, SEER and a Phase II NCI Trial

Abstract 3: (215) MGMT Promoter Methylation Status Independently Predicts Overall Survival in Anaplastic Astrocytoma in NRG Oncology/RTOG 9813: A Phase III Trial of Radiation Plus Nitrosourea Versus Radiation Plus Temozolomide

Abstract 4: (342) The Risk of Radiation Necrosis Following Stereotactic Radiosurgery with Concurrent Systemic Therapies

Abstract 5: (1007) Focal Management of Large Brain Metastases and Risk of Leptomeningeal Disease

Abstract 6: (1006) Implications of HER2 Status on Local Control and Adverse Radiation Effects After Stereotactic Radiosurgery for Brain Metastases of Breast Cancer

Abstract 7: (337) Phase I Study of Spinal Cord Constraint Relaxation with Single Session Spine Stereotactic Radiosurgery in the Primary Management of Patients with Inoperable, Previously Unirradiated Metastatic Epidural Spinal Cord Compression

Abstract 8: (339) Imaging-based Outcomes for 24 Gy in 2 Daily Fractions for Patients with De Novo Spinal Metastases Treated with Spine Stereotactic Body Radiation Therapy: An Emerging Standard
Abstract 1: (232) Improving Quality and Consistency in Clinical Trials Via Knowledge-based Planning, NRG Oncology RTOG 0631

Abstract 2: (99) Incident Learning for Stereotactic Radiation Therapy from RO-ILS: Radiation Oncology Incident Learning System®

Abstract 3: (101) Radiogenomic Analysis of a Peritumoral CT Image Feature and Its Prognostic Value in Early Stage NSCLC

Abstract 4: (102) Diffusion Imaging Biomarkers of Regional White Matter Injury Correlate with Change in Executive Function and Processing Speed After Brain Radiation Therapy

Abstract 5: (106) Regional Dose Differences Associated with Radiation-induced Acute Severe Dysphagia
Kontakt: bestof@multiscan.cz, dolezelm@email.cz
Doc. MUDr. Martin Doležel, Ph.D.
KOC Pardubického kraje, Kyjevská 44,
532 03 Pardubice
www.multiscan.cz

Kongresové centrum Kunětická Hora Dříteč
Dříteč 155, 533 05
GPS: 50°6'41.669"N, 15°49'9.128"E
http://grkh.cz/kongres/

Vzdělávací akce je pořádána dle Stavovského předpisu ČLK č.16,
bude ohodnocena příslušným počtem kreditů.

Výše účastnického poplatku je 150 Kč (platba na místě).

Prosím o elektronické přihlášení na mail (dolezelm@email.cz či bestof@multiscan.cz),
nejpozději do 12. 3. 2018.